Firestone Institute for Respiratory Health

Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support

Retrieved on: 
星期三, 十月 25, 2023
Patient, Research, COPD, McMaster Faculty of Engineering, Faculty, Engineering, McMaster University, Therapy, Periodic breathing, Firestone Institute for Respiratory Health, Transfusion-related acute lung injury, Life, Hope, McMaster, Student, Fibrosis, St. Joe, Health, Quality of life, St. Joseph's Healthcare Hamilton, Caregiver, Internet, Disease, Boehringer Ingelheim, Emotion, Confusion, Market access, Asthma, Partnership, ILD, Depression, Anxiety, Diagnosis, Empathy, Associate, Uncertainty, Mental health, Medical device, Nursing, BURLINGTON, Medicine

"Having the opportunity to work with ILD patients has been a deeply humbling and rewarding experience.

Key Points: 
  • "Having the opportunity to work with ILD patients has been a deeply humbling and rewarding experience.
  • "ILD is a complex, life-altering disease where Canadians often do not get the information they need at diagnosis.
  • Boehringer Ingelheim Canada, St. Joseph's Healthcare Hamilton, and McMaster University are committed to transforming the ILD patient experience.
  • Research is wide-ranging, from basic studies of animal models of lung disease (asthma, COPD, fibrosis) to clinical trials, epidemiological studies, and evaluative research.

Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights

Retrieved on: 
星期三, 十一月 9, 2022
Avenanthramide, Income, GLOBE, McMaster University, SA, YTD, Firestone Institute for Respiratory Health, Division, AVA, Pathology, Alginic acid, Pharmacokinetics, CTA, Safety, Department, Coenzyme Q10, Technology, Particle size, Health Canada, Jefferson Healthcare Hospital, The Company, CZO, YBG, Saint Joseph, Molecular medicine, Agriculture and Agri-Food Canada, Litre, Polymer, Fluid mechanics, Mitacs, Company, D, Saint Joseph's, Journal, Research, MBA, University, GMP, Letter, CEO, Organic acid, Oil, Management, Pharmaceutical industry, Beer, Fine chemical, Tolerability, Agriculture

EDMONTON, Alberta, Nov. 09, 2022 (GLOBE NEWSWIRE) --  Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2022.

Key Points: 
  • A response from Health Canada for clearance to proceed with this study is expected to be received within 90 days.
  • The second GMP clinical batches will also be manufactured, packaged and labeled in 2023 by Corealis Inc. GMP Manufacturing Services.
  • Financial Highlights for the Third Quarter and Nine-Month Period Ended September 30, 2022
    Total sales of $3,845,000 for the third quarter of 2022 and $15,517,000 for the first nine months of 2022 compared to $4,523,000 and $13,633,000 for the comparative periods in 2021.
  • Cash flows generated from operations of $5,644,000 for the first nine months in 2022 vs $2,837,000 in 2021.

Sensational artemisinin-piperaquine for treatment of COVID-19 in prospect

Retrieved on: 
星期三, 十一月 3, 2021
People, Coronavirus, Research, Artemisinin, National Medical Products Administration, Guangzhou University, Guangzhou Medical University, Disease, Association, Tablet, Firestone Institute for Respiratory Health, Guangzhou University of Chinese Medicine, Infection, Joint Medical Service (Germany), TCM, Efficacy, National Health Commission, Genetics, Malaria, Hospital, Social media, International Journal of Antimicrobial Agents, COVID-19, Safety, Antimicrobial, Xinhui People's Hospital, Observation, Artemisia annua, Treatment, Canadian International Council, Pharmaceutical industry

These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".

Key Points: 
  • These drugs first came to the industry's attention after the International Journal of Antimicrobial Agents published a paper titled "Safety and Efficacy of Artemisinin-Piperaquine for Treatment of COVID-19".
  • This implies how the scientific community and the general public are in desperate need of effective drug treatments for COVID-19.
  • And they have been the drug of first choice recommended by the National Health Commission of China since 2009.
  • Going ahead, the drug is expected to have a greater role to play in the treatment of other diseases," said Zhu Layi, president of Guangdong New South Group.

Convexity Scientific Teams with Right2Breathe During National Asthma and Allergy Awareness Month

Retrieved on: 
星期三, 四月 29, 2020
Health, Respiratory therapy, Medicine, Medical specialties, Asthma and Allergy Foundation of America, Respiratory therapist, Respiratory disease, Nebulizer, Asthma, Dutch hypothesis, Firestone Institute for Respiratory Health

FAIRFIELD, Conn., April 29, 2020 /PRNewswire/ --Convexity Scientific, a leader in innovative respiratory technologies today announced a partnership with Right2Breathe in support of National Asthma and Allergy Awareness Month during the month of May.

Key Points: 
  • FAIRFIELD, Conn., April 29, 2020 /PRNewswire/ --Convexity Scientific, a leader in innovative respiratory technologies today announced a partnership with Right2Breathe in support of National Asthma and Allergy Awareness Month during the month of May.
  • Flyp is the world's first truly pocket portable nebulizer helping patients manage asthma, chronic obstructive pulmonary disease (COPD) and other respiratory disorders.
  • While the month of May is designated as asthma and allergy awareness month, those of us with loved ones who live with respiratory disease are aware of the daily struggles that patients and families face."
  • The Asthma and Allergy Foundation of America has issued a report listing the top metropolitan cities where living with asthma is challenging.

Spirometers Industry Insights & Projections to 2025 - Rise in Prevalence of COPD, Growing Preference for Home Healthcare

Retrieved on: 
星期五, 三月 20, 2020
Pulmonology, Chronic lower respiratory diseases, Medicine, Respiratory diseases, Health, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic condition, Respiratory disease, Pulmonary disease, chronic obstructive, severe early-onset, Firestone Institute for Respiratory Health

The spirometers market will show rapid growth due to the rise in the prevalence of chronic obstructive pulmonary disease (COPD), technological advancements in the field of spirometers and growing preference for home healthcare.

Key Points: 
  • The spirometers market will show rapid growth due to the rise in the prevalence of chronic obstructive pulmonary disease (COPD), technological advancements in the field of spirometers and growing preference for home healthcare.
  • According to the World Health Organization (WHO), the global burden of disease study reported a prevalence of 251 million cases of COPD, globally, in 2016.
  • North America has dominated the spirometers market and the dominance of the market is mainly attributable to the increasing prevalence of respiratory diseases.
  • Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market.

Ethris and Munster University Hospital Receive ZIM Grant for Rare Pulmonary Disease Research

Retrieved on: 
星期二, 十月 1, 2019
Biotechnology, Health, Genetics, Pharmaceutical, Respiratory diseases, Pulmonology, Idiopathic pulmonary fibrosis, Respiratory disease, Pulmonary fibrosis, Respiratory therapy, Respiratory system, Organ systems, Firestone Institute for Respiratory Health

Ethris GmbH , a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, announced today that its existing collaboration with the laboratory of Prof. Heymut Omran at the Munster University Hospital has been awarded a research grant by the Central Innovation Program for SMEs (ZIM).

Key Points: 
  • Ethris GmbH , a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, announced today that its existing collaboration with the laboratory of Prof. Heymut Omran at the Munster University Hospital has been awarded a research grant by the Central Innovation Program for SMEs (ZIM).
  • Under the ZIM framework, companies and the research institutes they work with can be awarded grants for ambitious R&D projects.
  • Ethris is developing a portfolio of SNIM RNA therapies for pulmonary diseases including respiratory ciliopathies.
  • In addition, the company is researching SNIM RNA therapies for treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis exclusively with AstraZeneca under a five-year collaboration.